Twist Bioscience

Twist Bioscience manufactures synthetic DNA on its own silicon platform and offers protein expression as well as antibody and characterization services. This allows the company to translate AI-designed DNA and protein sequences into real, testable biology and places it at the interface that is crucial for accelerated drug development. Analysts see significant growth potential in AI-assisted research. » More on finanzen.net

Twist Bioscience was engaged as the preferred data provider for Eli Lilly’s TuneLab platform, strengthening its role in AI-powered drug discovery. Q3 revenue rose 23% to $118.38 million, and the outlook for 2026 was noticeably raised. Despite slightly missing the EPS target, the improved gross margin of 52.8% and the AI boom drew increased investor interest. » More on finanzen.net

Twist Bioscience will supply antibody characterization services and high-throughput wet‑lab data to Lilly's TuneLab and its AbLab developability model, allowing TuneLab users to order Twist's protocols and data to support AI-enabled antibody discovery. The collaboration positions Twist as a data-generation and antibody‑characterization provider within the AI-driven drug discovery ecosystem and could create incremental service revenue if TuneLab adoption rises. The agreement contains no disclosed minimum purchase commitments, milestones, or commercialization economics, so near‑term revenue impact is uncertain and depends on user demand for Twist's services. » More on finance.yahoo.com